Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $7.5

Benzinga Newsdesk www.benzinga.com Negative 72.9%

Neg 72.9% Neu 0% Pos 0%

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:TDOC) with a Neutral and lowers the price target from $11 to $7.5.